JNJ-8902 / J&J, Genmab - LARVOL DELTA

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Oncology • Solid Tumor

A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. (PubMed, Oncologist) - "In this study, dose escalation was limited by emerging dose-limiting toxicities. Although a recommended phase II dose was not determined, findings indicate TMEFF2 to be a potential target in mCRPC that warrants further investigation."

Journal • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • EGF • TMEFF2

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov) - P1 | N=80 | Enrolling by invitation | Sponsor: Janssen Research & Development, LLC

New P1 trial • Acute Myelogenous Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Castration-Resistant Prostate Cancer • Chronic Lymphocytic Leukemia • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Dec 2024 ➔ Jun 2025

Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Sep 2023 ➔ Dec 2024

Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Sep 2023 ➔ Dec 2024

Metastases • Trial completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jun 2023 ➔ Sep 2023

Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Jun 2023 ➔ Sep 2023

Metastases • Trial completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jan 2023 ➔ Jun 2023

Metastases • Trial primary completion date • Oncology • Solid Tumor

Pharmacodynamics of JNJ-70218902, a TMEFF2 × CD3 bispecific antibody, in cynomolgus monkey (SITC 2022) - P1 | "Ethics Approval The procedures involving the care and use of animals in this study were reviewed and approved by CR-MWN Institutional Animal Care and Use Committee before conduct (Testing Facility Study Number 886-526). During the study, the care and use of animals were conducted with guidance from the guidelines of the USA National Research Council."

IO biomarker • PK/PD data • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD4 • CD69 • CD8 • EGF • FOXP3 • GZMB • IL2RA • TMEFF2

Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models (AACR 2022) - P1 | "Targeting TMEFF2 with the TMEFF2 × CD3 bispecific antibody JNJ-902 elicited robust T cell-mediated responses in both prostate cancer cells and xenograft models. Based on these data, a phase 1 dose escalation trial of JNJ-902 in patients with mCRPC is currently ongoing (NCT04397276)."

Late-breaking abstract • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CASP3 • CD8 • EGF • GZMB • IFNG • IL10 • IL2RA • TMEFF2 • TNFA

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Jan 2023 ➔ Jun 2023

Trial completion date • Oncology • Solid Tumor

JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study (ESMO 2022) - P1 | "Part 1 (dose escalation) is ongoing and Part 2 (dose expansion) of study will initiate once part 2 expansion dose is declared. Selection of part 2 expansion dosage is currently being adjusted and dose information will be presented."

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • TMEFF2

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting | N=120 ➔ 82 | Trial completion date: Aug 2023 ➔ Jan 2023

Enrollment change • Enrollment closed • Trial completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Nov 2022 ➔ Aug 2023

Trial completion date • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=70 ➔ 120

Enrollment change • Oncology • Solid Tumor

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Janssen Research & Development, LLC; Not yet recruiting ➔ Recruiting

Enrollment open • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • KLK3

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: Janssen Research & Development, LLC

New P1 trial • Neuroendocrine Tumor • Oncology • Solid Tumor